Erzi Powder Veterinary Grade API is an active pharmaceutical ingredient supplied as a powder for downstream manufacture into 7 dosage-form presentations: tablets, injections, capsules, powders, granules, premixes, and solutions. The product designation itself functions as the commercial model identifier; no additional numerical model suffix appears in the technical file. The powder is manufactured under EU GMP Part II / ICH Q7 conditions and is intended for further processing rather than direct administration. Injectable use requires subsequent dissolution, bioburden control, and terminal sterilization or aseptic filtration; the API is not presented as sterile.

The specification framework for this multi-route grade includes identification, assay, chromatographic purity, residual solvents, water content, inorganic impurities, and particle-size characteristics. Because exact acceptance values depend on the veterinary monograph and target species, lot release is governed by the manufacturer’s certificate of analysis against the applicable Ph. Eur. general monograph “Substances for pharmaceutical use” and VICH GL18 guidance. Published data for this specific configuration is limited where the molecular entity or species-specific maximum residue limit is not stated; the following pharmacopoeial and processing boundaries should therefore be treated as route-specific requirements rather than absolute values for every batch.

What Physicochemical Metrics Must Be Maintained Across Routes?

Particle-size distribution is controlled by laser diffraction according to Ph. Eur. 2.9.31. Bulk density and tapped density are determined by Ph. Eur. 2.9.34, and flow rate by Ph. Eur. 2.9.36. The compressibility index and Hausner ratio are calculated from these densities. For direct compression, a Hausner ratio below 1.25 generally permits acceptable die fill on rotary tablet presses; between 1.25 and 1.40 the powder may still be processed with a forced feeder; above 1.40, granulation is normally required to avoid weight variation. These thresholds are processing guidance derived from pharmacopoeial flow classification, not an absolute release criterion for the API.

The release specification for a multi-route API therefore does not rely on a single tableting flow value; it requires a compatibility statement for each dosage form. A batch with a high Hausner ratio may still be released for solution or injection use if particle-size and endotoxin requirements are met, while the same batch may be restricted from direct compression without granulation. Route assignment must be stated on the certificate of analysis when the product is released for only a subset of the listed presentations.

VICH GL18 Residual Solvents, Endotoxins, and Sterility Assurance Boundaries

Residual solvent control follows VICH GL18 harmonised guidance. Class 1 solvents are controlled at the individual ppm limits; Class 2 solvents are limited by permitted daily exposure; Class 3 solvents are accepted up to 5000 ppm unless a higher limit is justified by batch data. For injectables, bacterial endotoxin limits are derived from the maximum dose and the target species weight, not from a universal API limit. The final injectable solution must comply with particulate matter limits for subvisible particles under Ph. Eur. 2.9.19. If the powder is non-sterile, terminal moist-heat sterilization at 121 °C for 15 min is acceptable only when the active substance is thermally stable; heat-labile molecules require aseptic filtration through a 0.22 µm membrane after dissolution. Sterility assurance is a finished-product requirement under Ph. Eur. 5.1.1, not an API release test.

Differences from single-route powders are concentrated in this cluster of tests. A premix-only powder may be released with lower endotoxin or particulate oversight, whereas a powder intended for injectable manufacture must control bioburden, endotoxin, and insoluble material sufficiently to avoid failing final-product clarity or depyrogenation. Conversely, a solution-only API may be micronized and static-prone, which impairs tablet and capsule flow. The Erzi Powder Veterinary Grade API is therefore specified across the broadest common denominator of the seven intended routes.

On a high-speed rotary tablet press with B-tooling, die fill variation becomes visible when API blend flow falls below pharmacopoeial pass thresholds. Direct compression blends containing this powder require forced feeder speed adjustment if bulk density shifts by more than 10% between lots. In capsule filling with dosator nozzles, powder bed height and compression stroke must be adjusted to tapped density; a Hausner ratio above 1.35 may require tamping-pin fillers or wet granulation. These are practical processing boundaries observed on industrial filling and compression lines, not a property of the API molecule.

For wet granulation, the powder is combined with a binder solution in a high-shear mixer; the endpoint is controlled by impeller power draw or torque rather than fixed time. Over-wetting beyond the plateau of the power-consumption curve produces dense granules that can prolong tablet disintegration. Dry granulation by roller compaction is preferred when the API is moisture-sensitive or when residual water content must remain below the monograph limit. The powder should be conditioned at 25 °C and 60% relative humidity only if the certificate of analysis confirms stability; otherwise, lower-humidity handling is required.

The distinction from a conventional technical-grade powder is not merely quality control; it affects manufacturing cost and equipment choice. A technical-grade material may contain residual fines or agglomerates that increase the probability of blinding a 0.22 µm sterilizing-grade filter. A feed-grade premix powder may be acceptable for oral powders but lacks injectable endotoxin control. The Erzi designation indicates a grade whose release specification has been extended to cover injectable and solution routes without abandoning flow properties required for tablets and capsules. The trade-off is that a broader specification may require tighter supplier controls on particle-size lot-to-lot variability, particularly for direct compression customers.

Batch-to-batch variation in particle-size distribution is the principal source of downstream processing drift. If D50 shifts by more than 15% between lots, tablet hardness may require compression force adjustment, and capsule fill weight may require dosing chamber changes. A documented particle-size control range is therefore more important than any single target value. Vendor change control under EU GMP Part II requires that any mill or sieve change be evaluated for impact on flow and blend uniformity before release to multiple-route customers.

When Particle Size and Flow Conflict in Direct Compression and Premix Manufacture

A single particle-size distribution cannot simultaneously maximise flow for direct compression and dissolution for injectable solution. Coarse fractions above 200 µm generally flow well but dissolve slowly; fines below 75 µm improve active surface area but may reduce flow and increase dust. The appropriate D50 for a given lot is therefore set by the intended route and not by a general API criterion. If the product is to be used interchangeably across all seven presentations, a controlled span below 2.0 and a D50 near the median of the route-specific ranges is a practical compromise, but this compromise must be confirmed by application-specific process validation.

If the API is moisture-sensitive, the drying step after wet granulation must be controlled to a narrow bed-temperature window, typically ±5 °C around the validated set point. A lower temperature may leave residual moisture that initiates hydrolysis; a higher temperature may induce polymorphic change or chemical degradation. The dryer inlet air dew point should be below the equilibrium moisture limit for the product. These processing constraints are route-dependent and must be established by forced-degradation and sorption isotherm studies, not assumed from the powder’s visual appearance.

On a twin-screw continuous granulation line, feeding consistency is governed by the loss-in-weight feeder fill factor. A powder with high fine content may require gravimetric feeder agitation and enclosed hopper inserts to prevent bridging. In batch premix production with ribbon blenders, segregation can occur if the API particle size and carrier particle size differ by more than an order of magnitude; geometric dilution and stepwise sieving reduce assay variability. Blend uniformity acceptance typically uses 10 sampling points with individual results between 90.0% and 110.0% of the labelled claim and a relative standard deviation not greater than 5.0%, unless the veterinary monograph specifies otherwise.

For injectable solution preparation, the powder is dissolved in water for injection or a suitable co-solvent. The solution is filtered through a 0.22 µm membrane before aseptic filling if the molecule is heat-sensitive. Filter compatibility is evaluated by measuring bubble point before and after filtration under ASTM F838-20, and the filter area must be matched to solution viscosity and particulate burden. Solutions and premixes prepared from this API are not interchangeable with sterile injectable solutions unless the final product has been terminally sterilized or aseptically processed under Ph. Eur. 5.1.1. The powder should not be combined with strong oxidizers, acid chlorides, or other reactive excipients unless binary compatibility studies confirm the absence of degradation products. Because the specific molecular structure is not defined in the product name, formulators must run forced-degradation and excipient-compatibility screens under Ph. Eur. 2.2.29 before committing to a formulation.